Review Article

Specificity of Methylation Assays in Cancer Research: A Guideline for Designing Primers and Probes

Zeinab Barekati, Ramin Radpour, Corina Kohler, and Xiao Yan Zhong

Laboratory for Gynecological Oncology, Women’s Hospital and Department of Biomedicine, University of Basel, Basel 4031, Switzerland

Correspondence should be addressed to Xiao Yan Zhong, zhongx@uhbs.ch

Received 20 February 2010; Accepted 21 June 2010

Academic Editor: Shi-Wen Jiang

DNA methylation is an epigenetic regulation mechanism of genomic function, and aberrant methylation pattern has been found to be a common event in many diseases and human cancers. A large number of cancer studies have been focused on identification of methylation changes as biomarkers (i.e., breast cancer). However, still clinical use of them is very limited because of lack of specificity and sensitivity for diagnostic test. This highlights the critical need for specific primer and probe design to avoid false-positive detection of methylation profiling. The guideline and online web tools that are introduced in this paper might help to perform a successful experiment and to develop specific diagnosis biomarkers by designing right primer pair and probe prior to experimental step.

1. Introduction

DNA methylation of cytosine located 5’ to a guanosine is one of the most important modifications of genomic DNA in eukaryotic cells. Methylation of cytosine at CpG dinucleotides is described as an epigenetic regulation mechanism of genomic function that plays an important role in different biological processes including embryogenesis [1], genomic imprinting [2], X-chromosome inactivation, and cancer [3, 4].

Aberrant methylation pattern has been found to be a common event in many cancers [5–7]. Global hypomethylation is considered to play a role in carcinogenesis; however, local hypermethylation changes gene expression [8]. This hypermethylation alteration resulted in transcriptional inactivation followed by silencing of promoter at nearby tumor suppressor genes, contributing to development of cancer. The hypermethylation was thought to be an early event in carcinogenesis [9–12]. A large number of studies in cancers including breast cancer have focused on the use of CpG island hypermethylation profiling as cancer biomarkers in tissue and circulating cell-free DNA of patients, with the aim of improving cancer treatment via accurate early diagnosis, noninvasive diagnosis, prognosis, and prognosis therapy selection [7, 13–18].

Recent technology development has provided the analysis of DNA methylation in a genome-wide scale [19, 20] which may not be easily accessible for many institutions. Thereby, in most of the research centers methylation assays can be only determined on gene-by-gene-based methods that use bisulfite conversion. The bisulfite reaction was first described in early 1970s [21, 22]. Since the first description of bisulfite reaction in the application of studying CpG sites, many methods based on the same principle have been developed and categorized according to primer designing strategies. Based on primer designing strategies two different DNA methylation assays are described, methylation-independent-specific PCR (MIP) primers and methylation-specific PCR (MSP) primers [23].

Primer and probe design for methylation assays based on bisulfite conversion is challenging because of the DNA composition after bisulfite modification. One of the most critical steps for methylation study is designing primers and probes for the modified DNA and it needs special constrains on primers or probe and their location on the DNA. A large number of studies have been focused on identification of
biomarkers; however, the clinical use of these biomarkers is still very limited because of lack of specificity and sensitivity for diagnostic test. This highlights the critical need for specific primer and probe design to avoid false-positive detection of methylation.

We review a brief guideline of CpG island prediction, designing primers and probes for MIP and MSP assays that are used for methylation studies based on bisulfite conversion. Some important web-tools for methylation studies are introduced as well.

2. CpG Island Prediction

Methylation at the cytosine bases of CpG dinucleotide-rich region mostly within 0.5–4 kb are known as CpG islands [24, 25]. Although analysis of the methylation status of some critical CpG sites as biomarkers are better than others, it is essential to find CpG islands at the promoter region of candidate genes which are in close proximity to the transcription start site.

In order to predict CpG islands as target region, the following rules should be applied.

(I) If CpG island prediction is used for primer design and more than one island is found, any of the predicted islands can be a target region for primer selection.

(II) If a CpG island size is smaller than the minimum product size, the primer pair should span the whole island.

(III) If a CpG island size is greater than the maximum product size, the primer pair should be within the island.

(IV) If a CpG island size is between the minimum and maximum product size, at least two thirds of the island region should be amplified.

3. Methylation-Independent-Specific PCR (MIP) Primers

MIP primers are used in different PCR-based methylation analysis methods including bisulfite-sequencing PCR (BSP) (in 1992, [26]), pyrosequencing [27, 28], combined bisulfite restriction analysis (COBRA) [29], methylation-sensitive single-nucleotide primer extension (MS-SnuPE) [30–32], methylation-sensitive melting curve analysis (MS-MCA) [33], methylation-sensitive high-resolution melting (MS-HRM) [34], matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry with base-specific cleavage and primer extension [35, 36], heavy methyl [37], and microarray DNA methylation profiling technique based on bisulfite conversion, that is, methylation-specific oligonucleotide microarray (MSO) [38].

Incomplete bisulfite modification of DNA is sometimes a concern [39] and results in high representation of methylation levels in studied samples. Successful application of MIP methods depends on whether PCR primer could be designed to amplify the complete modified fragment of interest.

To reduce bias of bisulfite-modified DNA against unmodified or incompletely modified DNA or even unsuccessful experimental PCR optimization, primer pair should be picked from a region that have adequate number of cytosines “C”s (no-CpG) in the original sequence [40]. Primer pairs with more “C”s will be preferred by receiving higher weighing scores and increasing the annealing temperature (Table 1). Besides general consideration for designing primer pair, the following constraints are enforced for MIP primer design.

(I) Primers should not contain any CpG sites within their sequence to avoid discrimination against methylated or unmethylated DNA (Figure 1).

(II) Primers should have an adequate number of “C”s (no-CpG) in their sequence to amplify only bisulfite modified DNA. Primers with more “C”s will be preferred (at least 30%) [40] (Figure 1).

(III) A good primer pair should span a maximal number of CpG sites in the selected amplicon to map as many CpG sites as possible.

(IV) If CpG island prediction is not used for primer selection, selected amplicons must span at least 5 CpG sites as a default.

(V) Long length primer (25–30 mer) is preferred to ensure uniqueness of the primer [39].

(VI) Primer sets should not amplify more than 500 bp because DNA degradation occurs by bisulfite modification.
Figure 1: Primer design for DNA methylation profiling techniques based on bisulfite conversion. (a) First DNA is treated with sodium bisulfite to convert all unmethylated cytosines to uracil. To analyze DNA methylation status of the interest genes, converted DNA is amplified based on two different primer designing strategies: methylation-independent specific PCR (MIP) and methylation-specific PCR (MSP). (b) In MIP, DNA molecules are amplified using primer pairs containing cytosines (no-CpG) in their sequence. (c) In MSP, primer pairs are designed to specifically amplify either methylated (M) or unmethylated (U) DNA by containing CpG site in their sequence that makes possible to distinguish the methylated sequence from the unmethylated sequence.

4. Methylation-Specific PCR (MSP) Primers

Methods based on MSP primers are considered to have the highest analytical sensitivity and are designed to specifically amplify either methylated or unmethylated DNA by using primers that distinguish the methylated sequence from the unmethylated sequence [23, 40]. The precision and sensitivity of MSP depends on appropriate primer or probe design not prone to false-positive results [23]. MSP primers-based methods include methylation-specific PCR (MSP) [40], methylight [41, 42], SYBER green-based quantitative MSP [43, 44], sensitive melting analysis after real-time MSP (SMART-MSP) [45], and methylation-specific fluorescent amplicon generation (MS-FLAG) [46]. The specificity of methylation-based PCR methods is achieved by appropriate primer pair or probes design (Table 1). The following constraints are recommended to reduce false-priming events for amplification of methylated DNA.

(I) To discriminate between a methylated and unmethylated DNA fragment, primers have to contain as much CpG sites as possible (at least one CpG) preferably at the very 3′-end. At least one of the last three bases at 3′-end of the primer has to be a CpG “C” (Figure 1).

(II) A part from CpG site(s) at the very 3′-end, additional CpG sites in a primer sequence is preferred (Figure 1).

(III) Primers for methylated DNA and unmethylated DNA should contain the same CpG sites in their sequence. For example, a forward primer for methylated pair has this sequence: ATAGTTAATGTTGTCGA, the forward primer in the unmethylated pair must also contain the two CpG sites, for example, ATAGTTAATGGTTTGA. But they may differ in length and start position [3].

(IV) The two sets of primers for methylated and unmethylated DNA should have similar Tm values (max Tm difference 5°C).

(V) Elimination of secondary structure formation and primer-dimer pairs by increasing primer length.

(VI) Primer sets should not amplify more than 500 bp because DNA degradation occurs by bisulfite modification.

False-priming event can be prevented by designing appropriate primers and increasing annealing temperature. Having an appropriate negative control in the experiment might help to find out false-priming events.

5. Guidelines for Probe Designing

In methylation studies, the discrimination between methylated and unmethylated DNA is achieved by three ways:
design of primers that contain or does not contain CpG sites, design of fluorescent labeled probe (for instance MSO and bead array), and design of the both primer and probe, that is, methylight technology [41]. MIP and MSP methods are associated with false positive results. By using fluorescent probes, for instance methylight methodology or applying heavy methyl probe-based methodology, the false positives can be limited. Using probe as a detection method increases the specificity to discriminate between methylated and unmethylated DNA by designing probes that contain additional CpG sites [40]. The selection of new primer pairs for methylation-specific PCR and suitable hybridization probes for real-time PCR-based assays require the identification of the CpG sites that are methylated (Table 1). Moreover, using probe provides possibility to detect more than one target with multiplex reaction by different reporter dyes [38, 47].

In addition probe-based assays can provide quantitative information; further advantages are the speed and high throughput of the 96-well-based, real-time PCR system and the omission of all postamplification steps, which has less labour and the risk of contamination. Also, the efficiency of individual reactions is accessible from the slope of the amplification plot in the logarithmic phase. This allows for the direct quality control of every amplification reaction and the identification of samples containing impurities or poor template that interfered with optimal amplification and thereby with the quantification [48].

A general guideline for probe designing is described as follows.

(I) The probe sequences should include 3 to 5 potential methylation sites to maximize specificity and reduce false-priming event.

(II) The probe binding sites should include several cytosines in the original sequence to ensure specificity for converted DNA and overcome false positives due to incomplete bisulfite conversion.

(III) Long repetitive stretches should be avoided.

(IV) Probe Tm value should be 10°C higher than primers.

(V) G + C content should be 30%–80%.

(VI) No G should be at the 5′ end.

(VII) Probes should have 15–30 mer in length.

(VIII) No more than two G + C should be at the 3′ end.

(IX) Amplicon size should be 50–150 bp (max 300 bp). The PCR products should be as short as possible, to maximize efficiency (especially important for the analysis of fragmented DNA isolated from formalin-fixed, paraffin-embedded biopsies, and circulating cell-free DNA).

6. Online Web Tools for Methylation Study

6.1. DNA Methylation Analysis Databases

(i) Entrez Gene: (http://www.ncbi.nih.gov/entrez).

(ii) GDB: Human Genome Database (http://www.gdb.org/).

(iii) DNA methylation database: public resource to store and standardise DNA methylation data (http://www.methdb.de/).

(iv) methBLAST: similarity search program designed to explore in silico bisulfite modified DNA, either or not methylated at its CpG dinucleotides (http://medgen.ugent.be/methBLAST/).

(v) DNA Methylation Society: an international scientific society open to all those interested in any aspects of biological methylation (http://www.dnamethylation.net/).

6.2. Promoter Prediction Tools

(i) FirstEF: first-exon and promoter prediction program for human DNA (http://rulai.cshl.org/tools/FirstEF/).

(ii) Promoter 2.0 Prediction Server: Promoter 2.0 predicts transcription start sites of vertebrate PolII promoters in DNA sequences (http://www.cbs.dtu.dk/services/Promoter/).

(iii) WWW Promoter Scan: predicts Promoter regions based on scoring homologies with putative eukaryotic Pol II promoter sequences (http://thr.cit.nih.gov/molbio/proscan/).

(iv) McPromoter MM: The Markov Chain Promoter Prediction Server. McPromoter is a program aiming at the exact localization of eukaryotic RNA polymerase II transcription start sites (http://genes.mit.edu/McPromoter.html).

6.3. CpG Island Prediction Tools

(i) CpG Island Searcher (http://cpgislands.usc.edu/).

(ii) CpG Plot (http://www.ebi.ac.uk/emboss/cpgplot/).

(iii) MethPrimer (http://www.urogene.org/methprimer/).

(iv) CpGProD (CpG Island Promoter Detection): CpGProD is a mammalian-specific software which proposes to identify the promoter regions associated with CpG islands (CGIs). CpGProD uses the structural characteristics of the CGIs associated with promoters (start CGIs). In the first step, CpGProD searches for all the CGIs located over the sequences and, in the second step, CpGProD identifies start CGIs and orientation of the potential promoters (http://pbil.univ-lyon1.fr/software/).

(v) CpG island Explorer for local installation (http://www.hku.hk/).
6.4. Methylation PCR Primer Design Tools

(i) MethPrimer: CpG island prediction, MSP, MSI primer design. By using this software 5’t and 3’ends of primer pair should have sites where conversion has occurred (C to T). This is to avoid amplification bias towards the unconverted sequence (http://www.urogene.org/methprimer/).

(ii) BiSearch: BSP and MSP primer design (http://bisearch.enzim.hu/).

(iii) PerlPrimer: PerlPrimer is a free, open-source application written in Perl that designs primers for standard PCR, bisulfite PCR, real-time PCR (QPCR) and sequencing. It aims to automate and simplify the process of primer designing (http://perlprimer.sourceforge.net/).

(iv) BiQ Analyzer: software tool for easy visualization and quality control of DNA methylation data from bisulfite sequencing (http://biq-analyzer.bioinf.mpi-inf.mpg.de/).

6.5. Methylation BLAST (metthBLAST). metthBLAST (http://medgen.ugent.be/metthBLAST/) is a sequence similarity search program designed to explore in silico bisulfite modified DNA (either or not methylated at its CpG dinucleotides) to provide a search portal for validated methylation assays. The tool is mainly developed to find primer binding sites and hence addresses specificity for PCR-based assays that use bisulfite converted DNA as input material, including bisulfite sequencing, methylation-specific PCR, COBRA, bisulfite-PCR-SCCP (BiPS), Ms-SNuPE, and PCR melting curve analysis.

7. Discussion

The large number of investigations such as human epigenome project (HEP) and cancer studies focused on DNA methylation analysis based on bisulfite modification provided valuable information about methylation variable positions that might influence genes activity (http://www.epigenome.org) [7, 16, 49, 50]. Increasing knowledge about methylation status of genes involved in carcinogenesis can lead to discovering new biomarkers that could be used for early detection, management, diagnosis or therapeutic approaches in cancer patients. Developing biomarkers by methylation analyzing methods requires accuracy, sensitivity, low-false-positive and false-negative rates and high-throughput evaluation of single CpG sites. Although different useful technologies exist for methylation assessment, no method is universal. While besides choosing a method according to type of samples and possessed laboratory special equipment, right choice of CpG island and primer or probe will minimize the risk of failed experiment.

Right primer and probe design is crucial for successful PCR amplification of bisulfite-modified DNA. Bisulfite reaction not only causes the expected conversion of cytosines to uracils, but also causes undesired DNA strand breakage. Loss of DNA during the subsequent purification step is another concern especially when studying microdissected DNA samples. All these factors pose challenges to downstream PCR applications and primacy of designing primers and probe for such PCR-based assays. Mostly, amplification of a product size greater than 500 bp is difficult after bisulfite-modified DNA template; hence, it might be better to set the default product size range as 100–500 bp for primer design. Another option that differs from standard PCR is primer length. Bisulfite conversion-based PCRs generally require longer primers. Primers with a length of approximately 30 mer usually yield successful results [39]. The reason is that bisulfite modification decreases considerably GC content of DNA templates and produces long stretches of “T”s in the sequence that makes it difficult to pick primers with acceptable Tm values or stability. In other words, in order to discriminate modified DNA and unmodified or incompletely modified DNA, enough number of “C”s is required in primers and probes, which makes picking stable primers more demanding. Thus, to achieve better duplex stability, choosing longer primer is necessary as Tm of DNA. In practice, size of primers for such PCR-based assays usually ranges from 20 to 30 mer [3, 40, 51].

Much more effort is needed to validate an experiment for clinical use of biomarkers such as easy to use method, sensitivity and specificity, appropriate primers and probes, easily interpretable results, and cost-effectiveness. The guidelines and the online web tools that are introduced in this review might help to have a successful experiment and to develop specific diagnosis biomarkers by designing right primer pair and probe prior to experimental step.

References

[1] M. Monk, M. Boubelik, and S. Lehnert, “Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development,” Development, vol. 99, no. 3, pp. 371–382, 1987.
[2] J. Singer-Sam and A. D. Riggs, “X chromosome inactivation and DNA methylation,” EXS, vol. 64, pp. 358–384, 1993.
[3] L.-C. Li, R. Chui, K. Nakajima, B. R. Oh, H. C. Au, and R. Dahiya, “Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression,” Cancer Research, vol. 60, no. 3, pp. 702–706, 2000.
[4] D. Nojima, K. Nakajima, J. Franks, et al., “CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma,” Molecular Carcinogenesis, vol. 32, no. 1, pp. 19–27, 2001.
[5] A. Bird, “DNA methylation patterns and epigenetic memory,” Genes and Development, vol. 16, no. 1, pp. 6–21, 2002.
[6] Z.-J. Liu and M. Maekawa, “Polymerase chain reaction-based methods of DNA methylation analysis,” Analytical Biochemistry, vol. 317, no. 2, pp. 259–265, 2003.
[7] R. Radpour, Z. Barekati, C. Kohler, W. Holzgreve, and X. Y. Zhong, “New trends in molecular biomarker discovery for breast cancer,” Genetic Testing and Molecular Biomarkers, vol. 13, no. 5, pp. 565–571, 2009.
[8] M. Esteller, “Epigenetics in cancer,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1148–1159, 2008.
[9] M. Esteller, M. Sanchez-Cespedes, R. Resell, D. Sidransky, S. B. Baylin, and J. G. Herman, “Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients,” Cancer Research, vol. 59, no. 1, pp. 67–70, 1999.

[10] M. J. Fackler, M. McVeigh, J. Mehrotra et al., “Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer,” Cancer Research, vol. 64, no. 13, pp. 4442–4452, 2004.

[11] P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002.

[12] M. Widschwendter and P. A. Jones, “DNA methylation and breast carcinogenesis,” Oncogene, vol. 21, no. 35, pp. 5462–5482, 2002.

[13] A. Aggerholm, M. S. Holm, P. Guldberg, L. H. Olesen, and P. Hokland, “Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients,” European Journal of Haematology, vol. 76, no. 1, pp. 23–32, 2006.

[14] P. W. Laird, “The power and the promise of DNA methylation markers,” Nature Reviews Cancer, vol. 3, no. 4, pp. 253–266, 2003.

[15] R. Radpour, M. M. Haghibi, A. X.-C. Fan et al., “High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip,” Molecular Cancer Research, vol. 6, no. 11, pp. 1702–1709, 2008.

[16] R. Radpour, C. Kohler, M. M. Haghibi, A. X. C. Fan, W. Holzgreve, and X. Y. Zhong, “Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array,” Oncogene, vol. 28, no. 33, pp. 2969–2978, 2009.

[17] H. Shi, M. X. Wang, and C. W. Caldwell, “CpG islands: their potential as biomarkers for cancer,” Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 519–531, 2007.

[18] J. Yu, Y. Y. Cheng, Q. Tao et al., “Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer,” Gastroenterology, vol. 136, no. 2, article e1, pp. 640–651, 2009.

[19] L. Shen and R. A. Waterland, “Methods of DNA methylation analysis,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 5, pp. 576–581, 2007.

[20] D. Zilberman and S. Henikoff, “Genome-wide analysis of DNA methylation patterns,” Development, vol. 134, no. 22, pp. 3959–3965, 2007.

[21] H. Hayatsu, Y. Wataya, K. Kai, and S. Lida, “Reaction of sodium bisulfite with uracil, cytosine, and their derivatives,” Biochemistry, vol. 9, no. 14, pp. 2858–2865, 1970.

[22] R. Shapiro and J. M. Weissgraber, “Bisulfite-catalyzed transamination of cytosine and cytidine,” Biochemical and Biophysical Research Communications, vol. 40, no. 4, pp. 839–843, 1970.

[23] L. S. Kristensen and L. L. Hansen, “PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment,” Clinical Chemistry, vol. 55, no. 8, pp. 1471–1483, 2009.

[24] M. Esteller and J. G. Herman, “Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors,” Journal of Pathology, vol. 196, no. 1, pp. 1–7, 2002.

[25] D. Takai and P. A. Jones, “Comprehensive analysis of CpG islands in human chromosomes 21 and 22,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 6, pp. 3740–3745, 2002.

[26] M. Frommer, L. E. McDonald, D. S. Millar et al., “A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands,” Proceedings of the National Academy of Sciences USA, vol. 89, no. 5, pp. 1827–1831, 1992.

[27] S. Colella, L. Shen, K. A. Baggerly, J.-P. J. Issa, and R. Krahe, “Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites,” Biotechniques, vol. 35, no. 1, pp. 146–150, 2003.

[28] J. Tost, J. Dunker, and I. G. Gut, “Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing,” Biotechniques, vol. 35, no. 1, pp. 152–156, 2003.

[29] Z. Xiong and P. W. Laird, “COBRA: a sensitive and quantitative DNA methylation assay,” Nucleic Acids Research, vol. 25, no. 12, pp. 2532–2534, 1997.

[30] O. El-Maarri, U. Herbrinaux, J. Walter, and J. Oldenburg, “A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites,” Nucleic Acids Research, vol. 30, no. 6, p. e25, 2002.

[31] M. L. Gonzalez and P. A. Jones, “Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE),” Nucleic Acids Research, vol. 25, no. 12, pp. 2529–2531, 1997.

[32] Z. Wu, J. Luo, Q. Ge, and Z. Lu, “Microarray-based Ms-SNuPE: near-quantitative analysis for a high-throughput DNA methylation,” Biosensors and Bioelectronics, vol. 23, no. 9, pp. 1333–1339, 2008.

[33] J. Worm, A. Aggerholm, and P. Guldberg, “In-tube DNA methylation profiling by fluorescence melting curve analysis,” Clinical Chemistry, vol. 47, no. 7, pp. 1183–1189, 2001.

[34] I. L. Gandloto, T. Mikespa, P. Hokland, and A. Dobrovic, “Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene,” Epigenetics Chromatin, vol. 1, p. 7, 2008.

[35] M. Ehrlich, M. R. Nelson, P. Stamssens et al., “Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 15785–15790, 2005.

[36] D. van den Boom and M. Ehrich, “Mass spectrometric analysis of cytosine methylation by base-specific cleavage and primer extension methods,” Methods in Molecular Biology, vol. 507, pp. 207–227, 2009.

[37] S. E. Cottrell, J. Distler, N. S. Goodman et al., “A real-time PCR assay for DNA-methylation using methylation-specific blockers,” Nucleic Acids Research, vol. 32, no. 1, p. e10, 2004.

[38] D. Zhou, W. Qiao, Y. Wan, and Z. Lu, “Microarray-based Ms-SNuPE: near-quantitative analysis using dual-color fluorescence hybridization,” Journal of Biochemical and Biophysical Methods, vol. 66, no. 1–3, pp. 33–43, 2006.

[39] S. J. Clark, J. Harrison, C. L. Paul, and M. Frommer, “High sensitivity mapping of methylated cytosines,” Nucleic Acids Research, vol. 22, no. 15, pp. 2990–2997, 1994.

[40] J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996.

[41] C. A. Eads, K. D. Danenberg, K. Kawakami et al., “MethyLight: a high-throughput assay to measure DNA methylation,” Nucleic Acids Research, vol. 28, no. 8, p. E32, 2000.

[42] Y. M. D. Lo, I. H. N. Wong, J. Zhang, M. S. C. Tein, M. H. L. Ng, and N. M. Hjelm, “Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific
polymerase chain reaction," Cancer Research, vol. 59, no. 16, pp. 3899–3903, 1999.

[43] M. W. Chan, E. S. Chu, K. F. To, and W. K. Leung, "Quantitative detection of methylated SOCS-1 , a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection," Biotechnology Letters, vol. 26, no. 16, pp. 1289–1293, 2004.

[44] D.-C. Chu, C.-K. Chuang, J.-B. Fu, H.-S. Huang, C.-P. Tseng, and C.-F. Sun, “The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma,” Journal of Urology, vol. 167, no. 4 I, pp. 1854–1858, 2002.

[45] L. S. Kristensen, T. Mikeska, M. Krypuy, and A. Dobrovic, "Sensitive melting analysis after real time-methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection," Nucleic Acids Research, vol. 36, no. 7, article e42, 2008.

[46] C. Bonanno, E. Shehi, D. Adlerstein, and G. M. Makrigiorgos, "MS-FLAG, a novel real-time signal generation method for methylation-specific PCR," Clinical Chemistry, vol. 53, no. 12, pp. 2119–2127, 2007.

[47] B. N. Trinh, T. I. Long, and P. W. Laird, “DNA methylation analysis by methylight technology,” Methods, vol. 25, no. 4, pp. 456–462, 2001.

[48] U. Lehmann, B. Hasemeier, R. Lilischkis, and H. Kreipe, "Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens," Laboratory Investigation, vol. 81, no. 4, pp. 635–637, 2001.

[49] Z. Barekati, R. Radpour, C. Kohler, et al., “Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations,” Human Molecular Genetics, vol. 19, no. 15, pp. 2936–2946, 2010.

[50] R. Radpour, Z. Barekati, M. M. Haghighi et al., “Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer,” Modern Pathology, vol. 23, no. 5, pp. 763–772, 2010.

[51] J. R. Graff, J. G. Herman, S. Myöhänen, S. B. Baylin, and P. M. Vertino, “Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation,” Journal of Biological Chemistry, vol. 272, no. 35, pp. 22322–22329, 1997.